Common Contracts
6 similar Equity Distribution Agreement contracts by Altimmune, Inc., IMV Inc., Arvinas, Inc., Day One Biopharmaceuticals, Inc.
ALTIMMUNE, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • February 28th, 2023 • Altimmune, Inc. • Pharmaceutical preparations • New York
DAY ONE BIOPHARMACEUTICALS, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • June 1st, 2022 • Day One Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York
As further set forth in this agreement (this “Agreement”), Day One Biopharmaceuticals, Inc., Delaware corporation (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. and JonesTrading Institutional Services LLC (together, the “Agents” and each individually, an “Agent”), as sales agents, the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of shares of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agents shall have no obligation in connection with such compliance.
ARVINAS, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • August 6th, 2021 • Arvinas, Inc. • Pharmaceutical preparations • New York
As further set forth in this agreement (this “Agreement”), Arvinas, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. and Cantor Fitzgerald & Co. (each, an “Agent”, and together, the “Agents”), as sales agent, the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate gross offering price of up to $300,000,000 (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and neither of the Agents shall have any obligation in connection with such compliance.
ALTIMMUNE, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • February 25th, 2021 • Altimmune, Inc. • Pharmaceutical preparations • New York
EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • June 30th, 2020 • IMV Inc. • Pharmaceutical preparations • New York
As further set forth in this agreement (this “Agreement”), IMV Inc., a company organized under the laws of Canada (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. (the “Agent”), as sales agent, the common shares in the capital of the Company (the “Common Shares”), having an aggregate offering price of up to U.S. $24,500,000, (such Common Shares to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Each of the Company and the Agent hereby agrees and acknowledges that all sales and solicitation of sales of Shares shall be made solely in the United States and sales and solicitation of sales of Shares shall not be made in Canada or through the facilities of the Toronto Stock Exchange (the “TSX” or any other Canadian trading market (together with the TSX, a “Canadian Market”)). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 3(b) of
EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • March 18th, 2020 • IMV Inc. • Pharmaceutical preparations • New York
As further set forth in this agreement (this “Agreement”), IMV Inc., a company organized under the laws of Canada (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. (the “Agent”), as sales agent, the common shares in the capital of the Company (the “Common Shares”), having an aggregate offering price of up to U.S. $30,000,000, (such Common Shares to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Each of the Company and the Agent hereby agrees and acknowledges that all sales and solicitation of sales of Shares shall be made solely in the United States and sales and solicitation of sales of Shares shall not be made in Canada or through the facilities of the Toronto Stock Exchange (the “TSX” or any other Canadian trading market (together with the TSX, a “Canadian Market”)). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 3(b) of
